-
Mashup Score: 0
■ Salvat Laboratories announced submission of its NDA for the first ocular corticosteroid formulated in a nanoemulsion to treat inflammation and pain in post–ocular surgery patients. This submission is supported by 2 phase 3 clinical trials testing the corticosteroid nanoemulsion clobetasol in more than 400 US subjects from 40 centers, according to a company news release. The company’s patented…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Glaucoma Physician - Glaucoma Video Channel - 1 year(s) ago
Clinical success in early and moderate glaucoma patients Nathan Radcliffe, MD & Shan Lin, MD Practice philosophy and getting patients back into the office Nathan Radcliffe, MD & Mark Gallardo, MD Managing early to moderate glaucoma patients Nathan Radcliffe, MD & Jason Bacharach, MD The importance of better insurance access Nathan…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Drs. Radcliffe, Kinast, and Bacharach discuss recent innovations in #visualfield technology in part 32 of the Glaucoma Physician Video Channel. https://t.co/fa2paPEIp3 https://t.co/prgqEmQBIZ
-
-
Mashup Score: 0
■ If its recent NDA submission leads to FDA approval, Visiox Pharma’s PDP-716 (0.35% brimonidine tartrate), could be the market’s first once-daily brimonidine for glaucoma. The company said that the NDA submission is supported by data that showed IOP reduction for ocular hypertension and open-angle glaucoma while maintaining an excellent safety profile. “We believe the patented TearAct delivery…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
The Visiox TearAct technology uses fine resin particles as a vehicle for sustained release of brimonidine in a once-daily drop. Read more: https://t.co/1lfUg1IFHp #glaucoma #ophthalmology #ophthotwitter https://t.co/V8f0QPmemS
-
-
Mashup Score: 0Glaucoma Physician - Six-year Results from LiGHT Trial Confirm SLT’s Safety, Efficacy - 1 year(s) ago
■ In 2019, 3-year results from the LiGHT Trial found initial selective laser trabeculoplasty (SLT) treatment provided predominantly drop-free IOP control in almost 80% of eyes newly diagnosed with ocular hypertension (OHT) and open-angle glaucoma (OAG). This was coupled with a reduced need for glaucoma and cataract surgery vs initial drop regimens. Data indicated SLT may slow progression to more…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
“Drop-free IOP control and safety of SLT as a first-line treatment for OHT and OAG were confirmed." Read more: https://t.co/ZNsWfXl4xs
-
-
Mashup Score: 0
■ International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the Omni Surgical System from Sight Sciences, Inc., as a minimally invasive, implant-free standalone procedure for pseudophakic glaucoma patients. Specifically, patients in the study had a history of iStent or iStent Inject (Glaukos) implants and their pressure was no longer controlled by the…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
International Ophthalmology has published clinical data demonstrating safety and effectiveness of the Omni Surgical System from Sight Sciences, as a minimally invasive, implant-free standalone procedure for pseudophakic #glaucoma patients. Read more: https://t.co/YZdnFhiBuB https://t.co/amWbtttOtU
-
-
Mashup Score: 1Glaucoma Physician - Two-handed MIGS Possible With Gonio Ready - 1 year(s) ago
■ Oculus’s Gonio Ready allows MIGS surgeons to attach the gonio lens to the microscope. Without needing to hold the lens, they can perform 2-handed surgery. “Being able to use both hands for the MIGS operation opens up new possibilities for surgeons and adds a degree of safety for both the surgeon and the patient,” said Oculus CEO Christian Kirchhübel in a news release. “Our new Gonio Ready will…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
“Being able to use both hands for the MIGS operation opens up new possibilities for surgeons and adds a degree of safety for both the surgeon and the patient.” Read more: https://t.co/qZBZMNJDRJ https://t.co/LS1pJhH1cR
-
-
Mashup Score: 0
■ Although short-term overall success rates were high with either a second glaucoma drainage device (GDD) or transscleral cyclophotocoagulation (CPC) in eyes with inadequately controlled IOP, a second GDD was linked to more clinic visits and an increased risk of more glaucoma surgery. Writing in the Journal of Glaucoma, researchers said that both treatments were reasonable options for eyes with…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Researchers said that after a single #glaucoma drainage device (GDD), either a second GDD or transscleral cyclophotocoagulation were reasonable options for eyes with inadequately controlled IOP. Read more: https://t.co/kfJM2ozdiZ https://t.co/0yz3dmewWe
-
-
Mashup Score: 0Glaucoma Physician - Review Finds Substantial Research Gaps for Inequities in Eye Care - 1 year(s) ago
■ In a JAMA Ophthalmology editorial, reviewers delved into how patient inequities have been assessed and researched in ophthalmology. Encompassing a review of 75 publications, Hemmerich and colleagues found substantial research gaps regarding health inequities associated with the LGBTQ, Black, and Hispanic communities, and patients living in rural or underresourced areas. “Deficient…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
“The current landscape of equity in ophthalmic care has yet to be thoroughly investigated and is important to ensure inclusivity and patient-centered care.” Read more: https://t.co/ks1DEoxpev https://t.co/8zgcH4eRdJ
-
-
Mashup Score: 0
■ Compared with other specialties, ophthalmology programs rank last in underrepresented minority group recruitment, according to a study published in Ophthalmology. “We know from previous research that a diverse physician workforce that reflects our patient population can lead to decreased health care disparities, enhanced access to care, and improved patient outcomes and satisfaction,” said…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
About 19% of medical school attendees are underrepresented minorities, but they comprise only 6.3% of ophthalmology residency programs. Read more: https://t.co/ieINLJbI2V https://t.co/ZUvATfpaz6
-
-
Mashup Score: 0
SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform, a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to demonstrate significant intraocular pressure lowering in patients with glaucoma or ocular hypertension. The data were presented by Malik Y. Kahook, MD, cofounder,…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
“These data give a clear signal that the SpyGlass drug delivery system is a breakthrough platform technology with real potential to disrupt the way our most effective therapies are administered long-term." https://t.co/kg9MwFiFMt https://t.co/0gE39Kgg9f
-
Salvat Laboratories has submitted an NDA for the first ocular corticosteroid formulated in a nanoemulsion to treat inflammation and pain in post–ocular surgery patients. Read more: https://t.co/UeERnVkMqc https://t.co/jy54hJvm8e